The biologics contract development and manufacturing (CDMO) market is experiencing rapid growth and is dominated by global players with investments in large scale stainless steel capacity.
But is larger always better? Not necessarily says Celonic, a mid-sized, privately owned CDMO, who has been embracing next generation technologies to help small to large biotech customers bring their drugs reliably, effectively and efficiently to the market.
Spima Therapeutics starts with global licence agreement
Latest NewsSPIMA Therapeutics SA lauches with €1m investment by SATT AxLR, which has licenced the company’s lead programme, SP-001
EFSA updates guidelines on cultured proteins and Novel Food
Latest NewsThe EU’s food watchdog EFSA has updated its guidelines for novel food applications including cell-based and fermented foods to streamline approval times and clarify that food safety is its highest priority when recommending novel food products for market authorisation.
Patient-Centric CDMO Services – Expertise in Bioprocess Tech Transfers
Sponsored PublicationsAs a Contract Development and Manufacturing Organization (CDMO), mAbxience is committed to advancing biologics production and to ensuring that patients receive life-saving treatments faster and with uncompromising quality.
Lab Reagents made with ARTES – recombinant Proteins for lab research
ProductsARTES offers a brand-new business area making the hearts of all R&D staff beat faster. We have a whole range of first-class antigens, enzymes and functional proteins just waiting to be used in new, exciting projects.
Long version of The BIOSECURE Act: The West’s Wake-Up Call to China’s Biotech Dominance
Latest NewsBy Jeremy Levin, D.Phil, MB BChir
The importance of disaccharide excipients in biologics
Sponsored PublicationsDFE Pharma, a world leader in excipients, has expanded into the biopharmaceutical market with its BioHale® portfolio, specifically designed for biologics.
Asabys Partners close €180m Sabadell Asabys II Fund
Latest NewsAsabys Partners have announced the closing of a new oversubscribed fund aimed at investing in 12-15 companies across all areas of pharma biotech.
A “Pure Play” Biologics Swiss-based CDMO
Sponsored PublicationsThe biologics contract development and manufacturing (CDMO) market is experiencing rapid growth and is dominated by global players with investments in large scale stainless steel capacity.
But is larger always better? Not necessarily says Celonic, a mid-sized, privately owned CDMO, who has been embracing next generation technologies to help small to large biotech customers bring their drugs reliably, effectively and efficiently to the market.
The West’s wake-up call to China’s biotech dominance
BackgroundThe U.S. House of Representatives recently passed the BIOSECURE Act, prohibiting U.S. biopharma companies from working with Chinese contractors due to national security concerns, including data leaks and intellectual property theft. The Act is expected to pass the Senate.
White Paper: How Does PAT Apply to the Bioreactor?
Sponsored PublicationsDownload Hamilton’s comprehensive white paper and explore what PAT (Process Analytical Technology) means in Biopharma Upstream processes. Discover cutting-edge sensor solutions to effectively monitor critical process parameters and ensure product quality and reproducibility.